Researchers found that a new treatment called ersodetug may significantly improve blood sugar control in people with congenital hyperinsulinism (HI), a rare condition that leads to dangerously low blood sugar levels. In a recent study, participants taking ersodetug experienced notable reductions in hypoglycemia events and improvements in average blood glucose levels compared to those receiving a placebo. This could mean fewer episodes of low blood sugar, which can cause serious health issues, allowing individuals to manage their condition more effectively.

This study involved 63 participants aged 3 months to 45 years and showed that those on ersodetug had more than a 50% reduction in daily hypoglycemia events and a 10-15 mg/dL increase in average blood glucose levels. For individuals living with congenital HI, these improvements could translate into a better quality of life, reducing the need for other medications and treatments currently used to manage their condition.

The findings come from the Phase 3 sunRIZE study, which is a well-structured clinical trial. While the primary endpoint of the study was not statistically significant, the additional analyses showed promising results. The ongoing open-label extension phase of the study, where participants continue to receive treatment, suggests that the benefits of ersodetug may persist over time. However, more research is needed to fully confirm its effectiveness and safety in a broader population.

If you or someone you know is affected by congenital hyperinsulinism, staying informed about new treatments like ersodetug is essential. Discussing these developments with healthcare providers can help determine the best management strategies moving forward.

Source: globenewswire.com